Page 813 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

39. AGENTS RADIO ET CHIMIOSENSIBILISANTS 771

FUCHS T. et al., 3-amino-1,2,4-benzotriazine-4-oxide : characterization of a new meta-
bolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-ben-
zotriazine 1,4-dioxide (tirapazamine), J. Org. Chem., 2001, 66, 107-114.
• Propriétés pharmacologiques et mécanisme d'action
BAKER M.A. et al., Metabolism of SR 4233 by chinese Hamster ovary cells: basis of
selective hypoxie toxicity, Cancer res., 1988, 48, 5947-5992.
BROWN J.M., LEMMON M.J., Potentiation by the hypoxie cytotoxin SR 4233 of cell
killing produced by fractionated irradiation of mouse tumors, Cancer res., 1990, 50,
7747-7749.
FITZSIMMONS S.A. et al., Reduction of 3-amino-1,2,4-di-N-oxide (tirapaamine, Win
59075, SR 4233) to a DNA-damaging species : a direct role for NAPDH : Cytochrome
P 450 oxidoreductase, Carcinogenesis, 1994, 15, 1503-1510.
BROWN J.M., WANG L.-H., Tirapazamine : laboratory data relevant to clinical activity,
Anticancer Drug Des., 1998, 13, 529-539.
HWANG J.-T., GREENBERG M.M., Kinetics and stereoselectivity of thiol trapping of
deoxyuridin-1'-yl in biopolymers and their relationships to the formation of premuta-
genic a-deoxynucleotides, J. amer. Chem. Soc., 1999, 121, 4311-4315.
HWANG J.-T. et al., Reaction of the hypoxia-selective antitumour agent tirapazamine
with a C1'-radical in single-stranded and double-stranded DNA: the drug and its
metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA
damage reactions, Biochemistry, 1999, 38, 14248-14255.
JOUNAIDI Y., WAXMAN D. J., Combination of the bioreductive drug tirapazamine with
the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based
cancer gene therapy, Cancer Research, 2000, 60, 3761-3769.
SAUNDERS M.P. et al., Cytochrome C(P 450) reductase activates tirapazamine
(SR4233) to restore hypoxie and oxic cytotoxicity in an aerobic resistant derivatives
of the A549 cancer cell line, Br. J. Cancer, 2000, 82, 651-656.
COTTU P.H., Propriétés pharmacodynamiques et thérapeutiques de la tirapazamine
associée à la radiothérapie, in Eurocancer 2000, Libbey J., ed., eurotext Paris 2000,
59-60.
LARTIGAU E. et al., Survie in vitro « oxygène dépendante» de deux lignées humaines
après irradiation associée à la tirapazamine (SR-4233) et au cisplatine, Cancer/radio-
ther, 2000, 4, 217-22.
Von PAWEL J. et al., Tirapazamine plus cisplatin versus cisplatin in advanced non-small-
cell lung cancer: a report of the international CATAPULT I studygroup,J. Clin. Oncol.,
2000, 18, 1351-1359.
FUCHS T. et al., 3-amino-1,2,4-benzotriazine 4-oxide : characterization of a new meta-
bolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-ben-
zotriazine 1,4-dioxide (tirapazamine), J. Org. Chem., 2001, 66, 107-114.
• Relations structure-activité
MONGE A. et al., Hypoxia-selective agents derivated from quinoxaline 1,4-di-N-oxides,
J. Med. Chem., 1995, 38, 1786-1792.
MONGE A. et al., Hypoxia-selective agents derivated from 2-quinoxalinecarbonitrile 1,4-
di-N-oxides. 2, J. Med. Chem., 1995, 38, 4488-4494.